Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Invested Capital (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Invested Capital data on record, last reported at $52.9 million in Q3 2025.

  • For Q3 2025, Invested Capital rose 63.11% year-over-year to $52.9 million; the TTM value through Sep 2025 reached $52.9 million, up 63.11%, while the annual FY2024 figure was $43.2 million, 19.71% down from the prior year.
  • Invested Capital reached $52.9 million in Q3 2025 per PLX's latest filing, up from $49.9 million in the prior quarter.
  • Across five years, Invested Capital topped out at $69.9 million in Q1 2021 and bottomed at -$11.5 million in Q3 2022.
  • Average Invested Capital over 5 years is $29.6 million, with a median of $43.2 million recorded in 2024.
  • Peak YoY movement for Invested Capital: plummeted 433.55% in 2022, then soared 4880.75% in 2024.
  • A 5-year view of Invested Capital shows it stood at -$6.0 million in 2021, then crashed by 76.28% to -$10.6 million in 2022, then surged by 605.83% to $53.8 million in 2023, then dropped by 19.71% to $43.2 million in 2024, then rose by 22.44% to $52.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $52.9 million in Q3 2025, $49.9 million in Q2 2025, and $45.2 million in Q1 2025.